Efficacy of Genotype-matched Vaccine Against Re-emerging Genotype V Japanese Encephalitis Virus
Japanese encephalitis (JE), caused by the Japanese encephalitis virus (JEV), is a highly threatening disease with no specific treatment. Fortunately, the development of vaccines has enabled effective defense against JE. However, re-emerging genotype V (GV) JEV poses a challenge as current vaccines are genotype III (GIII)-based and provide suboptimal protection. Given the isolation of GV JEVs from Malaysia, China, and the Republic of Korea, there is a concern about the potential for a broader outbreak. Under the hypothesis that a GV-based vaccine is necessary for effective defense against GV JEV, we developed a pentameric recombinant antigen using cholera toxin B as a scaffold and mucosal adjuvant, which was conjugated with the E protein domain III of GV by genetic fusion. This GV-based vaccine antigen induced a more effective immune response in mice against GV JEV isolates compared to GIII-based antigen and efficiently protected animals from lethal challenges. Furthermore, a bivalent vaccine approach, inoculating simultaneously with GIII- and GV-based antigens, showed protective efficacy against both GIII and GV JEVs. This strategy presents a promising avenue for comprehensive protection in regions facing the threat of diverse JEV genotypes, including both prevalent GIII and GI as well as emerging GV strains.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Emerging microbes & infections - (2024) vom: 15. Apr., Seite 2343910 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kim, Jae-Deog [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Bivalent vaccine |
|---|
| Anmerkungen: |
Date Revised 15.04.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1080/22221751.2024.2343910 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM37108069X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM37108069X | ||
| 003 | DE-627 | ||
| 005 | 20240415234739.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240415s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/22221751.2024.2343910 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1376.xml |
| 035 | |a (DE-627)NLM37108069X | ||
| 035 | |a (NLM)38618740 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kim, Jae-Deog |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy of Genotype-matched Vaccine Against Re-emerging Genotype V Japanese Encephalitis Virus |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 15.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Japanese encephalitis (JE), caused by the Japanese encephalitis virus (JEV), is a highly threatening disease with no specific treatment. Fortunately, the development of vaccines has enabled effective defense against JE. However, re-emerging genotype V (GV) JEV poses a challenge as current vaccines are genotype III (GIII)-based and provide suboptimal protection. Given the isolation of GV JEVs from Malaysia, China, and the Republic of Korea, there is a concern about the potential for a broader outbreak. Under the hypothesis that a GV-based vaccine is necessary for effective defense against GV JEV, we developed a pentameric recombinant antigen using cholera toxin B as a scaffold and mucosal adjuvant, which was conjugated with the E protein domain III of GV by genetic fusion. This GV-based vaccine antigen induced a more effective immune response in mice against GV JEV isolates compared to GIII-based antigen and efficiently protected animals from lethal challenges. Furthermore, a bivalent vaccine approach, inoculating simultaneously with GIII- and GV-based antigens, showed protective efficacy against both GIII and GV JEVs. This strategy presents a promising avenue for comprehensive protection in regions facing the threat of diverse JEV genotypes, including both prevalent GIII and GI as well as emerging GV strains | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Bivalent vaccine | |
| 650 | 4 | |a Genotype V | |
| 650 | 4 | |a Japanese encephalitis virus | |
| 650 | 4 | |a Neutralizing antibody | |
| 650 | 4 | |a Recombinant vaccine | |
| 700 | 1 | |a Lee, Ah-Ra |e verfasserin |4 aut | |
| 700 | 1 | |a Moon, Dah-Hyun |e verfasserin |4 aut | |
| 700 | 1 | |a Chung, Young-Uk |e verfasserin |4 aut | |
| 700 | 1 | |a Hong, Su-Yeon |e verfasserin |4 aut | |
| 700 | 1 | |a Cho, Hyo Je |e verfasserin |4 aut | |
| 700 | 1 | |a Kang, Tae Hyun |e verfasserin |4 aut | |
| 700 | 1 | |a Jang, Yo Han |e verfasserin |4 aut | |
| 700 | 1 | |a Sohn, Myung Hyun |e verfasserin |4 aut | |
| 700 | 1 | |a Seong, Baik-Lin |e verfasserin |4 aut | |
| 700 | 1 | |a Seo, Sang-Uk |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Emerging microbes & infections |d 2012 |g (2024) vom: 15. Apr., Seite 2343910 |w (DE-627)NLM249608804 |x 2222-1751 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:15 |g month:04 |g pages:2343910 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/22221751.2024.2343910 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 15 |c 04 |h 2343910 | ||